These markers include FAT1 mutations, CD28 mutations in AITL, CDKN2A deletion in PTCL‐NOS, GATA‐3 expression, and TP63 structural abnormalities in ALK–ALCL (Table 5).24, 25, 26, 27, 28, 29, 30. This evidence concerns the gene TP63 and anaplastic large cell lymphoma.